€208.4m market cap

€2.49 last close

Transgene is a French company developing immunotherapy agents for cancer and infectious diseases.

Investment summary

Transgene is developing viral vector-based immunotherapies for combination therapies in oncology and infectious diseases. Next-generation platforms Invir.IO and myvac continue to progress. Transgene has announced a new collaboration and licensing agreement with AZN for its Invir.IO platform and received €10m on signing. Gross cash and short-term investments at 30 September 2019 were €53.9m. Transgene announced its Phase II trial combining TG4010 with Opdivo and chemotherapy in first-line NSCLC failed its primary endpoint and the company have ceased further development. We have placed our valuation under review.

Y/E Dec
Revenue (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2017A 8.1 (26.4) (35.0) (53.1) N/A N/A
2018A 42.9 9.1 (36.8) (44.7) N/A N/A
2019E N/A N/A N/A N/A N/A N/A
2020E N/A N/A N/A N/A N/A N/A
Industry outlook

Immunotherapies are one of the most promising classes of products for cancer. Increased attention is now being paid to the use of combination therapy approaches to improve cancer response rates.

Last updated on 25/03/2021
Register to receive research on Transgene as it is published
Share price graph
Balance sheet
Forecast net debt (€m) 13.7
Forecast gearing ratio (%) 19
Price performance
Actual 1.0 47.9 103.7
Relative* (1.6) 37.9 50.8
52-week high/low €2.8/€1.2
*% relative to local index
Key management
Philippe Archinard Chairman & CEO
Lucie Larguier Director of IR